Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cutting-Edge Lab Automation System Supports High-Volume Needs and Provides Faster Results

By LabMedica International staff writers
Posted on 19 Dec 2023

A new, innovative automation solution for clinical labs featuring smart technology can boost lab performance and flexibility, reduce turnaround time, and eliminate 80% of manual steps, thereby increasing reliability and minimizing errors to provide quicker lab results

Abbott’s (Lake Forest, IL, USA) GLP systems Track is a cutting-edge technology and scalable automation solution that helps laboratories meet high-volume demand and maximize productivity. More...

This system introduces innovative features that boost safety, productivity, and capacity to meet increasing laboratory demands. The flexibility of the GLP systems Track is a standout feature, offering laboratories the ability to tailor the system’s configuration to their specific requirements. A key innovation in this system is the CAR, a smart, self-propelled single sample carrier, which allows samples to move independently, not attached to rigid, fixed mechanized track systems. This innovation minimizes mechanical breakdowns that could halt operations, ensuring continuous functionality and adaptability to the lab's evolving needs.

Laboratory results influence up to 70% of medical decisions, and Abbott’s GLP systems Track significantly enhances healthcare quality by automating laboratory processes and aiming to reduce healthcare costs. Its state-of-the-art technology streamlines and simplifies lab tasks. This automation solution transforms sample sorting and transportation, allowing for automatic sample movement throughout the system. It is tailored to meet each lab's unique requirements, effectively managing demand and boosting overall output. The system integrates seamlessly with lab staff workflows, enhancing efficiency and safeguarding lab worker health by reducing direct contact with patient blood samples and lessening exposure to biomedical waste. Capable of handling up to 25,000 test tubes daily across various care settings, this system improves patient test result turnaround times. It also aids in decreasing operational expenses and minimizing manual errors. Abbott's GLP systems Track has received approval from the U.S. Food and Drug Administration (FDA) and is now available in the United States.

“We know that our customers are seeking flexibility and scalability in their laboratory operations so they can meet ever-growing demand,” said Louis Morrone, executive vice president for Abbott’s core diagnostics business. “GLP systems Track addresses those needs, enabling labs to increase performance and improve the overall quality of their operations.”

Related Links:
Abbott


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.